Table 1 Clinical features of patients infected or colonized with MRCoNS with reduced susceptibility to glycopeptides
Patients Strain No | Age/sex | Ward | Clinical feature | Underlying disease | Specimen | Duration of hospitalization (days) | Previous treatment with glycopeptide (days) | Treatment with glycopeptide (days) | Clinical outcome |
|---|---|---|---|---|---|---|---|---|---|
4504 | 46/F | Infectious Diseases | Pneumonia | Trauma | tracheal aspiration fluid | 20 | No | vancomycin (14) | Improved |
4505 | 33/M | Haematology | Septicemia | CML | Groin skin | 27 | No | No | NT |
4506 | 44/M | Haematology | Septicemia | AML | Abdominal wall skin | 46 | vancomycin (20) | No | NT |
4507 | 46/F | Haematology | Septicemia | ALL | Axilla skin | 60 | vancomycin (10) | No | NT |
4508 | 26/M | SICU | Septicemia | Trauma and Fracures Of mandibula and maxilla | Blood | 31 | No | vancomycin (10) | Improved |
4510 | 75/F | Infectious Diseases | Septicemia | Surgical operation of Colon | Blood | 6 | No | vancomycin (14) | Death not related to staphylococcal infection |